Neuroscience & CNS
Part of Biotech - Drug Development
 BIIB | Biogen Inc. Common Stock | $30.0b | $205.18 | -0.2% | 634.7K |
 NBIX | Neurocrine Biosciences Inc | $16.9b | $161.70 | -1.0% | 1.1M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.9b | $254.00 | -1.9% | 575.7K |
 AXSM | Axsome Therapeutics, Inc | $11.2b | $214.78 | -1.1% | 321.0K |
 CYTK | Cytokinetics Inc. | $10.5b | $80.21 | +3.5% | 2.2M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $8.5b | $364.00 | +15.7% | 1.3M |
 ALKS | Alkermes Inc. plc | $8.2b | $48.35 | -2.5% | 1.1M |
 TGTX | TG Therapeutics, Inc. | $7.1b | $49.50 | -0.6% | 1.1M |
 XENE | Xenon Pharmaceuticals Inc | $6.0b | $65.25 | +0.2% | 326.0K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $5.8b | $46.27 | +3.8% | 1.5M |
 PTCT | PTC Therapeutics, Inc. | $5.7b | $70.86 | +2.3% | 753.4K |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.7b | $38.68 | -0.2% | 2.2M |
 ACAD | Acadia Pharmaceuticals Inc. | $4.4b | $28.41 | -1.2% | 2.6M |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.7b | $25.45 | +1.5% | 2.6M |
 ALMS | Alumis Inc. Common Stock | $3.6b | $27.78 | +2.5% | 461.0K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $3.0b | $5.54 | -7.5% | 159.3K |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.7b | $46.80 | -0.3% | 1.2M |
 ATAI | AtaiBeckley Inc. Common Stock | $2.7b | $7.19 | -0.2% | 4.0M |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $2.3b | $24.10 | +10.7% | 3.1M |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $2.0b | $38.60 | +1.3% | 657.6K |
 BHVN | Biohaven Ltd. | $2.0b | $14.48 | +5.8% | 1.6M |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $2.0b | $46.80 | +9.3% | 331.0K |
 GHRS | GH Research PLC Ordinary Shares | $1.9b | $29.70 | +4.9% | 460.7K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.8b | $31.91 | -0.0% | 564.8K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.7b | $6.40 | -1.9% | 1.7M |
 LBRX | LB Pharmaceuticals Inc Common Stock | $1.1b | $48.18 | +7.3% | 440.3K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.1b | $29.62 | -18.5% | 2.0M |
 ANRO | Alto Neuroscience Inc. | $1.1b | $27.88 | +1.6% | 378.6K |
 TBPH | Theravance Biopharma, Inc. | $0.9b | $16.92 | +0.1% | 225.1K |
 ANNX | Annexon, Inc. Common Stock | $0.8b | $5.58 | +4.3% | 2.6M |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.7b | $80.83 | +1.3% | 135.7K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $0.6b | $15.34 | +0.7% | 181.2K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $0.6b | $13.44 | +2.8% | 405.0K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.6b | $5.07 | -1.3% | 781.2K |
 HELP | Cybin Inc. Common Stock | $484.7m | $10.93 | +5.4% | 3.5M |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $463.6m | $3.91 | +4.3% | 1.4M |
 PRTA | Prothena Corporation plc Ordinary Shares | $436.1m | $8.38 | +1.1% | 321.9K |
 OVID | Ovid Therapeutics Inc. Common Stock | $434.9m | $2.57 | +1.5% | 1.1M |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $342.3m | $2.42 | +0.8% | 343.9K |
 VNDA | Vanda Pharmaceuticals Inc. | $314.5m | $5.23 | +0.5% | 2.1M |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $303.9m | $1.65 | +1.9% | 281.2K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $260.9m | $3.46 | +0.1% | 577.1K |
 AVXL | Anavex Life Sciences | $254.8m | $3.29 | +2.5% | 784.9K |
 ACIU | AC Immune SA | $222.9m | $2.32 | +1.3% | 67.9K |
 NERV | Minerva Neurosciences, Inc | $185.0m | $4.42 | +2.1% | 239.9K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $181.3m | $3.13 | +0.6% | 367.7K |
 ACOG | Alpha Cognition Inc. Common Stock | $180.3m | $8.50 | 0.0% | 14.7K |
 NGEN | NervGen Pharma Corp. Common stock | $174.5m | $1.70 | +2.4% | 337.0K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $170.0m | $11.70 | +3.5% | 201.1K |
 ALEC | Alector, Inc. Common Stock | $167.6m | $1.90 | +24.8% | 5.6M |